Basit öğe kaydını göster

dc.contributor.authorKocatepe, Vildan
dc.contributor.authorURAS, Cihan
dc.contributor.authorSezgin, Derya Subaşı
dc.contributor.authorUSLU, Yasemin
dc.date.accessioned2023-05-29T12:02:13Z
dc.date.available2023-05-29T12:02:13Z
dc.date.issued2023
dc.identifier.citationUSLU Y., Kocatepe V., Sezgin D. S., URAS C., "Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors", Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, cilt.31, sa.5, ss.285, 2023
dc.identifier.issn1433-7339
dc.identifier.otherav_14758462-795c-4989-b1ab-992336464db4
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/188772
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/14758462-795c-4989-b1ab-992336464db4/file
dc.identifier.urihttps://doi.org/10.1007/s00520-023-07742-2
dc.description.abstractPURPOSE: Adjuvant endocrine therapy reduces the recurrence and mortality of early hormone receptor-positive breast cancer in both pre- and postmenopausal women. The aim of this study was to investigate adjuvant tamoxifen adherence and associated factors in breast cancer survivors. METHODS: This descriptive, prospective study was conducted in 2019-2020 with the participation of 531 women who survived breast cancer and were under follow-up at the Senology Institute of a hospital in Istanbul. Inclusion criteria were having completed treatment for early hormone receptor-positive breast cancer, being prescribed tamoxifen, and being 18 years or older. Data were collected using a patient information form and the Morisky Medication Adherence Scale-8 (MMAS-8). RESULTS: The mean age of the participants was 44.9 ± 6.5 years, and the mean duration of tamoxifen use was 834.4 ± 685.7 days. The women's mean MMAS-8 score was 6.86 ± 1.39. Medication adherence was significantly positively correlated with current age (p = 0.006) and age at diagnosis (p = 0.002). There was a statistically significant difference between tamoxifen adherence according to participants' employment status (p = 0.028), chronic disease status (p = 0.018), loss of libido (p = 0.012), treatment-related changes in mood changes (p = 0.004), and having negative effects affecting daily life (p < 0.001). CONCLUSION: Overall, breast cancer survivors in this study reported moderate adherence to tamoxifen. The women's individual characteristics and the adverse effects of treatment influenced medication adherence. Healthcare professionals can help increase adherence to this treatment, which reduces the risk of mortality, by explaining the importance of the medication, identifying and eliminating barriers to adherence, and informing women about evidence-based interventions to increase medication compliance.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectİç Hastalıkları
dc.titleAdherence to adjuvant tamoxifen and associated factors in breast cancer survivors
dc.typeMakale
dc.relation.journalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
dc.contributor.departmentİstanbul Üniversitesi , Hemşirelik Fakültesi , Cerrahi Hastalıklar Hemşireliği Anabilim Dalı
dc.identifier.volume31
dc.identifier.issue5
dc.identifier.startpage285
dc.identifier.endpage285
dc.contributor.firstauthorID4265532


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster